...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cell Research >Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185~(c―erbB―2)
【24h】

Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185~(c―erbB―2)

机译：抗肿瘤表面抗原p185〜（c―erbB‐2）工程抗体的构建，表达和表征

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The c-erbB-2 proto-oncogene encodes a 185kDa protein p!85, which belongs to epidermal growth factor receptor family. Amplification of this gene has been shown to correlate with poor clinical prognosis for certain cancer patients. The monoclonal antibody A21 which directed against p185 specifically inhibits proliferation of tumor cells overexpressing p185, hence allows it to be a candidate for targeted therapy. In order to overcome several drawbacks of murine MAb, we cloned its VH and V_L genes and constructed the single-chain Fv (scFv) through a peptide linker. The recombinant scFvA21 was expressed in Escherichia coli and purified by the affinity column. Subsequently it was characterized by ELISA, Western blot, cell immunohistochemistry and FACS. All these assays showed the binding activity to extracellular domain (ECD) of p185. Based on those properties of scFvA21, we further constructed the scFv-Fc fusion molecule with a homodimer form and the recombinant product was expressed in mammalian cells. In a series of subsequent analysis this fusion protein showed identical antigen binding site and activity with the parent antibody. These anti-p185 engineered antibodies have promised to be further modified as a tumor targeting drugs, with a view of application in the diagnosis and treatment of human breast cancer.
机译：c-erbB-2原癌基因编码一个185kDa蛋白p！85，属于表皮生长因子受体家族。已经显示该基因的扩增与某些癌症患者的不良临床预后相关。针对p185的单克隆抗体A21特异性抑制过表达p185的肿瘤细胞的增殖，因此使其成为靶向治疗的候选药物。为了克服鼠单克隆抗体的几个缺点，我们克隆了它的VH和V_L基因，并通过肽接头构建了单链Fv（scFv）。重组scFvA21在大肠杆菌中表达并通过亲和柱纯化。随后，通过ELISA，蛋白质印迹，细胞免疫组织化学和FACS对其进行表征。所有这些测定显示了对p185的细胞外结构域（ECD）的结合活性。基于scFvA21的那些特性，我们进一步构建了具有同型二聚体形式的scFv-Fc融合分子，并且重组产物在哺乳动物细胞中表达。在一系列后续分析中，该融合蛋白显示出与亲本抗体相同的抗原结合位点和活性。考虑到在人类乳腺癌的诊断和治疗中的应用，这些抗p185工程改造的抗体有望被进一步修饰为肿瘤靶向药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号